Emerging epigenomic landscapes of pancreatic cancer in the era of precision medicine. Nat Commun 2019 Aug 28;10(1):3875
Date
08/30/2019Pubmed ID
31462645Pubmed Central ID
PMC6713756DOI
10.1038/s41467-019-11812-7Scopus ID
2-s2.0-85071625821 (requires institutional sign-in at Scopus site) 79 CitationsAbstract
Genetic studies have advanced our understanding of pancreatic cancer at a mechanistic and translational level. Genetic concepts and tools are increasingly starting to be applied to clinical practice, in particular for precision medicine efforts. However, epigenomics is rapidly emerging as a promising conceptual and methodological paradigm for advancing the knowledge of this disease. More importantly, recent studies have uncovered potentially actionable pathways, which support the prediction that future trials for pancreatic cancer will involve the vigorous testing of epigenomic therapeutics. Thus, epigenomics promises to generate a significant amount of new knowledge of both biological and medical importance.
Author List
Lomberk G, Dusetti N, Iovanna J, Urrutia RAuthors
Gwen Lomberk PhD Professor in the Surgery department at Medical College of WisconsinRaul A. Urrutia MD Center Director, Professor in the Surgery department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
AnimalsAntineoplastic Agents
Clinical Trials as Topic
DNA Methylation
Disease Models, Animal
Epigenesis, Genetic
Epigenomics
Gene Expression Regulation, Neoplastic
Humans
Pancreatic Neoplasms
Precision Medicine
Treatment Outcome
